tetano
Editor, Senior Moderator
J Infect Dis. 2014 Nov 18. pii: jiu647. [Epub ahead of print]
Influenza Vaccine Effectiveness in the United States During 2012-13: Variable Protection by Age and Virus Type.
McLean HQ1, Thompson MG2, Sundaram ME1, Kieke BA1, Gaglani M3, Murthy K3, Piedra PA4, Zimmerman RK5, Nowalk MP5, Raviotta JM5, Jackson ML6, Jackson L6, Ohmit SE7, Petrie JG7, Monto AS7, Meece JK1, Thaker SN2, Clippard JR2, Spencer SM2, Fry AM2, Belongia EA1.
Author information
Abstract
BACKGROUND:
During the 2012-13 influenza season, there was co-circulation of A/H3N2 and two B lineage viruses in the United States.
METHODS:
Patients with acute cough illness ≤7 days duration were prospectively enrolled and swabbed at outpatient clinics in five states. Influenza vaccination dates were confirmed by medical records. Vaccine effectiveness (VE) was estimated as [100% x (1-adjusted odds ratio)] for vaccination in cases vs. test-negative controls.
RESULTS:
Influenza was detected in 2,307 (36%) of 6,452 patients; 1,292 (56%) had A/H3N2, 582 (25%) had B/Yamagata, and 303 (13%) had B/Victoria. VE was 49% (95% CI: 43, 55) overall; 39% (95% CI: 29, 47) against A/H3N2, 66% (95% CI: 58, 73) against B/Yamagata (vaccine lineage), and 51% (95% CI: 36, 63) against B/Victoria. VE against A/H3N2 was highest among persons aged 50-64 years (52%; 95% CI: 33, 65) and 6 months-8 years (51%; 95% CI: 32, 64) and lowest among those ≥65 years (11%; 95% CI: -41, 43). In younger age groups, there was evidence of residual protection from receipt of the 2011-12 vaccine one year earlier.
CONCLUSIONS:
The 2012-13 vaccines were moderately effective in most age groups. Cross-lineage protection and residual effects from prior vaccination were observed and warrant further investigation.
? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
PMID:
25406334
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25406334
Influenza Vaccine Effectiveness in the United States During 2012-13: Variable Protection by Age and Virus Type.
McLean HQ1, Thompson MG2, Sundaram ME1, Kieke BA1, Gaglani M3, Murthy K3, Piedra PA4, Zimmerman RK5, Nowalk MP5, Raviotta JM5, Jackson ML6, Jackson L6, Ohmit SE7, Petrie JG7, Monto AS7, Meece JK1, Thaker SN2, Clippard JR2, Spencer SM2, Fry AM2, Belongia EA1.
Author information
Abstract
BACKGROUND:
During the 2012-13 influenza season, there was co-circulation of A/H3N2 and two B lineage viruses in the United States.
METHODS:
Patients with acute cough illness ≤7 days duration were prospectively enrolled and swabbed at outpatient clinics in five states. Influenza vaccination dates were confirmed by medical records. Vaccine effectiveness (VE) was estimated as [100% x (1-adjusted odds ratio)] for vaccination in cases vs. test-negative controls.
RESULTS:
Influenza was detected in 2,307 (36%) of 6,452 patients; 1,292 (56%) had A/H3N2, 582 (25%) had B/Yamagata, and 303 (13%) had B/Victoria. VE was 49% (95% CI: 43, 55) overall; 39% (95% CI: 29, 47) against A/H3N2, 66% (95% CI: 58, 73) against B/Yamagata (vaccine lineage), and 51% (95% CI: 36, 63) against B/Victoria. VE against A/H3N2 was highest among persons aged 50-64 years (52%; 95% CI: 33, 65) and 6 months-8 years (51%; 95% CI: 32, 64) and lowest among those ≥65 years (11%; 95% CI: -41, 43). In younger age groups, there was evidence of residual protection from receipt of the 2011-12 vaccine one year earlier.
CONCLUSIONS:
The 2012-13 vaccines were moderately effective in most age groups. Cross-lineage protection and residual effects from prior vaccination were observed and warrant further investigation.
? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
PMID:
25406334
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25406334